All News
2025 ACR Guideline for the Treatment of SLE
The ACR has released its 2025 Systemic Lupus Erythematosus (SLE) treatment guidelines and consensus-based good practice statements, applicable to children and adults with SLE.
Read Article
Diagnosing Neuropsychiatric SLE (5.23.2025)
Dr. Jack Cush reviews the news and journal reports from RheumNow.com - including views on the vagus nerve, NPSLE and CAR-T mania.
Read Article
Panacea of Prednisone & Cannabis (5.16.2025)
Dr. Jack Cush reviews the news, journal and regulatory reports from this week on RheumNow.com. Interesting trends and results with prednisone in lupus, cannabis in RA and opioid deaths too!
Read Article
NEW for #LUPUS2025—@ern_reconnet–SLICC–@SLEuroSociety expert consensus on the therapeutic management of rare systemic #lupus erythematosus manifestations https://t.co/XwAHpsho57
Free to read with registration on https://t.co/28wkm5ab69 (also free)
@Lupusreference #SLE https://t.co/73K0DKTHye
Links:
The Lancet Rheumatology TheLancetRheum ( View Tweet)
Shifting the Management Paradigm for SLE and Lupus Nephritis
The paradigm for treating patients with systemic lupus erythematosus (SLE) is rapidly shifting and our patients will surely benefit with improved outcomes.
https://t.co/idxMBTyTwp https://t.co/unxmjVst3D
Dr. John Cush RheumNow ( View Tweet)
Emerging therapies targeting the NLRP3-inflammasome (active in Autoinflammatory Dz, Gout, neurodegenerative Dz/Alzheimers). Currently no FDA approved drugs, but many in trials. eg, Oxidized DNA (DAMP) activates NLRP3 & may be blocked by repurposed glycosylase inhibitors to reduce https://t.co/CJv50LVKhy
Dr. John Cush RheumNow ( View Tweet)
CAR-T and cellular depletion therapies gone wild! Currently there are over 85 different therapeutic candidates aiming to reset the immune system in >380 clinical trials. Review article looks at indications, targets, modalities & outlook. https://t.co/yleR4B48IY https://t.co/WwSPzIPomk
Dr. John Cush RheumNow ( View Tweet)
SLE Perspectives: Past, Present, Future
https://t.co/ggYmVvEtZx https://t.co/VriDjAEcl5
Dr. John Cush RheumNow ( View Tweet)
🔓 Lupus Unlocked: Antiphospholipid Syndrome
📅 Tuesday, May 20, 2025 | 🕕 Time: 6:00 PM CT | 7:00 PM ET | 4:00 PM PT
Live Webinar w/ Q&A
Register Today: https://t.co/71NJsmBNf3
Livestream: X, LinkedIn, YouTube, Facebook
This session is designed to provide practical insights https://t.co/jAtduyzl0l
Dr. John Cush RheumNow ( View Tweet)
Deep remission in SLE – what is it, and can we achieve it?
Recent reports on lupus patients treated with CAR-T cells targeting CD19+ B lymphocytes have sparked excitement. This is due to the patients experiencing ongoing clinical remission without further treatment after two https://t.co/rdBkIhfWWd
Dr. John Cush RheumNow ( View Tweet)
Single center study of 2741 ANA tests: 65% ANA negative, 31% ANA+ w/ nuclear staining patterns, & 2.0% ANA+ w cytoplasmic staining. Cytoplasmic - most were reticular, dense fine speckled next. Reticular assoc w/ primary biliary cholangitis (w/ Abs against M2). Dense fine https://t.co/SfBY9BShax
Dr. John Cush RheumNow ( View Tweet)
A brief history of familial Mediterranean fever - FMF is most common periodic fever syndr. an inherited polyserositis mainly affects Arabs, Armenians, Jews, & Turks. Hx may date back to 1802 & Heberden. Osler described 11 cases in 1895. 1st clear report 1945 by Siegal 10 pts. https://t.co/m20uO3bOoj
Dr. John Cush RheumNow ( View Tweet)
Single center study of 2741 ANA tests: 65% ANA negative, 31% ANA+ w/ nuclear staining patterns, & 2.0% ANA+ w cytoplasmic staining. Cytoplasmic - most were reticular, dense fine speckled next. Reticular assoc w/ primary biliary cholangitis (w/ Abs against M2). Dense fine https://t.co/JI7iGvw8xp
Dr. John Cush RheumNow ( View Tweet)
A brief history of familial Mediterranean fever - FMF is most common periodic fever syndr. an inherited polyserositis mainly affects Arabs, Armenians, Jews, & Turks. Hx may date back to 1802 & Heberden. Osler described 11 cases in 1895. 1st clear report 1945 by Siegal 10 pts. https://t.co/61WOxt9fPy
Dr. John Cush RheumNow ( View Tweet)
Full read overview of Discoid Lupus. https://t.co/G6lXWTRSFn https://t.co/yjVsDg0D5d
Links:
Dr. John Cush RheumNow ( View Tweet)
Full read overview of Discoid Lupus. https://t.co/aXgveR2NwF https://t.co/9JK6CNqedO
Links:
Dr. John Cush RheumNow ( View Tweet)
International Myositis Assessment and Clinical Studies Group (IMACS) reached a consensus on ‘anti-synthetase syndrome’ as the preferred nomenclature and "ASyS" as the preferred abbreviation for the ‘anti-synthetase syndrome. https://t.co/TuTzVVZzZO https://t.co/EJkxX6aP56
Dr. John Cush RheumNow ( View Tweet)
Arterial or venous thrombotic events (AVTEs) are common w/ new forms of monogenic vasculitis (DADA2 & VEXAS), resulting from pathogenetic mechanisms of endothelial dysfunction, immune complex deposition and pro-inflammatory cytokines. Reviewed here. https://t.co/Nw9wNYssg3 https://t.co/5V0yrctaFI
Dr. John Cush RheumNow ( View Tweet)
International Myositis Assessment and Clinical Studies Group (IMACS) reached a consensus on ‘anti-synthetase syndrome’ as the preferred nomenclature and "ASyS" as the preferred abbreviation for the ‘anti-synthetase syndrome. https://t.co/TuTzVVZzZO https://t.co/qs5f1qATKi
Dr. John Cush RheumNow ( View Tweet)
TONIGHT! Tuesday Night Rheumatology returns this month with the launch of Lupus Unlocked, starting with a special Journal Club session.
Join authors Dr. Richard Furie and Dr. Brad Rovin as they walk us through their pivotal studies on lupus nephritis:
📄 Obinutuzumab in Active https://t.co/REJQzVaslb
Dr. John Cush RheumNow ( View Tweet)
